Measles Virus

For adults who do not have evidence of immunity, the standard dosage is at least one dose of the Measles Virus vaccine (typically as MMR).

• Standard Dose: 0.5 mL administered subcutaneously.
• High-Risk Adults: Healthcare workers, international travelers, and students in post-secondary educational institutions should receive two doses, separated by at least 28 days.
• Evidence of Immunity: Adults born before 1957 are generally considered immune, though healthcare workers in this age group may still be required to show serologic evidence of immunity or receive the vaccine.

The pediatric schedule is the most common application of the Measles Virus vaccine.

• First Dose: 0.5 mL at age 12 through 15 months.
• Second Dose: 0.5 mL at age 4 through 6 years (before entering school).
• Early Administration: In outbreak settings or for international travel, infants aged 6 through 11 months may receive a 0.5 mL dose. However, these children must still receive the standard two-dose series starting at 12 months of age because the maternal antibodies present in younger infants may interfere with the immune response.

Renal Impairment

No dosage adjustments are required for patients with renal impairment. The vaccine does not rely on renal clearance.

Hepatic Impairment

No dosage adjustments are required for patients with hepatic impairment. However, patients with severe end-stage liver disease should be evaluated for overall immune competence before receiving a live virus vaccine.

Elderly Patients

Clinical studies have not identified significant differences in safety or efficacy between elderly and younger adults. However, the primary goal in elderly populations is ensuring that those without historical immunity are protected, especially if traveling.

Measles Virus vaccines must be administered by a licensed healthcare professional.

• Route: Subcutaneous (SC) injection is the only approved route. It is typically injected into the outer aspect of the upper arm (deltoid region) in adults and older children, or the anterolateral thigh in younger children.
• Reconstitution: The lyophilized (freeze-dried) powder must be reconstituted only with the diluent provided by the manufacturer. The diluent should be added slowly to the vial and agitated gently to ensure complete dissolution.
• Timing: The reconstituted vaccine should be used immediately. If not used within 8 hours, it must be discarded. It must be protected from light at all times.
• Storage: The lyophilized vaccine should be stored in a refrigerator or freezer (between -50°C and +8°C). The diluent can be stored at room temperature or in the refrigerator.

If a child or adult misses a scheduled dose, it should be administered as soon as possible. There is no need to restart the series regardless of the time elapsed between doses. A minimum interval of 28 days must be maintained between the first and second dose.

While an 'overdose' of a vaccine is rare, administration of a higher-than-recommended volume or an extra dose typically does not result in serious clinical sequelae. The primary risk is an increase in local injection site reactions or a more pronounced systemic 'flu-like' response. In the event of an accidental extra dose, the patient should be monitored for fever and localized pain.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip scheduled vaccinations without medical guidance. Vaccination is a critical component of community health.

Most individuals experience mild reactions following the administration of the Measles Virus vaccine. These are signs that the body is building protection.

• Injection Site Reactions: Redness, swelling, and soreness at the site of the needle stick. This typically occurs within 24 hours and lasts 1-2 days.
• Fever: A mild to moderate fever (up to 101°F or 38.3°C) may occur 7 to 12 days after vaccination. This is the period when the attenuated virus is replicating most actively.
• Mild Rash: A non-contagious, measles-like rash may appear in about 5% of recipients, usually 7 to 10 days after the injection.

• Joint Pain (Arthralgia): More common in adult women than in children, this typically affects the small joints of the hands and feet. It usually begins 1 to 3 weeks after vaccination and is transient.
• Swollen Glands: Lymphadenopathy (swollen lymph nodes) in the neck or jaw area.
• Irritability: Particularly in infants and toddlers during the febrile period.

• Febrile Seizures: In children, the risk of a seizure caused by fever increases slightly 5 to 12 days after the first dose of a measles-containing vaccine. According to the CDC (2023), this occurs in approximately 1 in 3,000 to 4,000 children.
• Immune Thrombocytopenic Purpura (ITP): A rare condition where the blood platelet count drops temporarily, which can lead to bruising or bleeding. This occurs in about 1 in 40,000 doses.
• Allergic Reactions: Hives or a mild wheeze shortly after injection.

> Warning: Stop taking Measles Virus (in the context of a multi-dose series) and call your doctor immediately if you experience any of these serious symptoms.

• Anaphylaxis: Signs include difficulty breathing, swelling of the face or throat, rapid heartbeat, and dizziness. This is an extreme emergency occurring in less than 1 in 1,000,000 doses.
• Encephalitis/Encephalopathy: Inflammation of the brain. While measles virus itself causes this in 1 in 1,000 natural cases, the vaccine strain causes it in less than 1 in 1,000,000 doses, so rarely that a definitive causal link is difficult to establish.
• Pneumonia: In severely immunocompromised individuals, the attenuated virus can cause lung infection.
• Severe Skin Reactions: Stevens-Johnson Syndrome (extremely rare cases reported post-marketing).

There are no proven long-term negative health effects associated with the Measles Virus vaccine. Extensive research, including a landmark Cochrane Review (2020) involving millions of children, has definitively shown no link between the measles vaccine and the development of autism, asthma, or type 1 diabetes. The primary long-term 'effect' is the persistence of IgG antibodies, providing lifelong protection against rubeola.

There are currently no FDA Black Box Warnings for the Measles Virus vaccine. However, the prescribing information contains strict contraindications for pregnant women and severely immunocompromised individuals due to the theoretical risk of extensive viral replication.

Report any unusual symptoms or reactions to your healthcare provider. You or your provider can also report side effects to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967.

Measles Virus is a live-attenuated vaccine. This means it contains a weakened but functional version of the virus. While safe for the vast majority of people, it requires careful screening of the patient's medical history to ensure their immune system can handle the viral replication required for immunity.

No FDA black box warnings for Measles Virus. The safety profile is well-established through decades of global use.

• Allergic Reactions / Anaphylaxis Risk: Patients with a history of anaphylactic reactions to neomycin (an antibiotic used in the production process) or gelatin must not receive the vaccine. While the vaccine is grown in chick embryo cell cultures, the American Academy of Pediatrics (AAP) states that most children with egg allergies can safely receive the vaccine without prior skin testing.
• Immunosuppression: Individuals with primary or acquired immunodeficiency (e.g., HIV/AIDS, leukemia, lymphoma, or those receiving high-dose systemic steroids or chemotherapy) should not receive this vaccine. The attenuated virus may replicate unchecked, leading to severe disease.
• Family History of Seizures: Parents should inform the provider if the child has a personal or family history of seizures. While the risk of febrile seizures is low, monitoring for fever post-vaccination is recommended.
• Thrombocytopenia: Patients with a history of low platelet counts (ITP) may be at an increased risk of recurrence following vaccination.

No routine laboratory monitoring (like blood counts) is required for healthy individuals receiving the vaccine. However, in specific clinical scenarios:

• Serologic Testing: Healthcare workers may require IgG titers to confirm immunity.
• Temperature Monitoring: Parents should monitor the child's temperature 5 to 12 days post-vaccination, the peak window for febrile reactions.

The Measles Virus vaccine has no known effect on the ability to drive or operate machinery. However, if a patient experiences syncope (fainting) immediately after the injection—a common vasovagal response in adolescents—they should wait until they are fully recovered.

There is no direct interaction between alcohol and the Measles Virus vaccine. However, excessive alcohol consumption can suppress the immune system, potentially resulting in a less robust antibody response to the vaccine.

As this is typically a two-dose series rather than a chronic medication, 'discontinuation' refers to failing to complete the series. Failure to receive the second dose leaves the individual at a 5% higher risk of contracting measles compared to those who complete the series.

> Important: Discuss all your medical conditions, including any history of immune system problems or recent blood transfusions, with your healthcare provider before starting the Measles Virus vaccination series.

• Immunosuppressive Therapies: Drugs such as cyclosporine, tacrolimus, azathioprine, and high-dose corticosteroids (e.g., prednisone >20mg/day for more than 2 weeks) can prevent the immune system from controlling the vaccine virus. This can lead to disseminated viral infection. Vaccination should be delayed until at least 3 months after stopping such therapies.
• Chemotherapy/Radiation: Live vaccines must be avoided during active cancer treatment and for at least 3 to 6 months following the completion of therapy.

• Immune Globulins and Blood Products: Antibodies present in blood products (whole blood, plasma, IVIG) can neutralize the attenuated Measles Virus before it can stimulate the host's immune system. According to the CDC's 'Pink Book,' vaccination should be delayed for 3 to 11 months after receiving blood products, depending on the type and dose of the product.
• Tuberculin Skin Test (TST/PPD): The Measles Virus vaccine can temporarily suppress the body's response to the TST, leading to a false-negative result. The TST should be performed either on the same day as vaccination or delayed for 4 to 6 weeks after vaccination.

• Other Live Vaccines: If Measles Virus is not given on the same day as other live vaccines (such as Varicella or Yellow Fever), the doses should be separated by at least 4 weeks to avoid interference between the two viruses.
• Salicylates (Aspirin): While primarily a concern with the Varicella component (due to Reye's Syndrome risk), it is generally advised to avoid aspirin-containing products for 6 weeks after receiving combination vaccines like MMRV.

There are no known food interactions with the Measles Virus vaccine. It can be administered regardless of the timing of meals.

• Echinacea: Some believe echinacea stimulates the immune system, but there is no clinical evidence that it affects the efficacy of the Measles Virus vaccine.
• High-dose Vitamin A: In children with actual measles infection, Vitamin A is therapeutic. However, there is no evidence that supplemental Vitamin A interferes with the vaccine's performance.

As mentioned, the Measles Virus vaccine can cause a temporary loss of tuberculin skin sensitivity. It does not typically interfere with standard chemistry or hematology panels, though a transient drop in white blood cell counts has been rarely noted in the first week post-vaccination.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, as well as any recent blood or plasma transfusions.

Measles Virus vaccine must NEVER be used in the following circumstances:

• Pregnancy: Because the vaccine contains a live virus, there is a theoretical risk to the fetus. Women should avoid becoming pregnant for at least 4 weeks after receiving the vaccine.
• Severe Immunodeficiency: This includes patients with AIDS, those with primary immunodeficiency syndromes (like SCID), and those on high-dose immunosuppressive drugs. The mechanism involves the risk of uncontrolled viral replication leading to systemic disease.
• Severe Allergic Reaction: A history of anaphylaxis to any component of the vaccine, including neomycin or gelatin.
• Active Untreated Tuberculosis: Although the vaccine does not exacerbate TB, clinical practice guidelines recommend initiating TB treatment before administering live vaccines.

These conditions require a careful risk-benefit analysis by a healthcare provider:

• Moderate or Severe Acute Illness: Vaccination should generally be deferred until the patient has recovered to ensure that side effects (like fever) do not complicate the clinical picture of the illness.
• Recent Blood Product Administration: As discussed, this may render the vaccine ineffective but is not 'dangerous' to the patient.
• History of ITP: The risk of a repeat drop in platelets must be weighed against the risk of contracting natural measles, which is much more likely to cause severe thrombocytopenia.

Patients who are sensitive to neomycin should be monitored closely or avoid the vaccine, as trace amounts are present from the manufacturing process. There is no cross-sensitivity with 'mycin' antibiotics like erythromycin or azithromycin, as they belong to different chemical classes.

> Important: Your healthcare provider will evaluate your complete medical history, including your family's history of immune disorders, before prescribing or administering the Measles Virus vaccine.

FDA Pregnancy Category C (Legacy): Measles Virus vaccine is contraindicated during pregnancy. While there have been no documented cases of 'Congenital Measles Syndrome' from the vaccine, the theoretical risk of live virus crossing the placenta is enough to mandate avoidance. If a pregnant woman is inadvertently vaccinated, she should be reassured that this is not generally considered an indication for termination of pregnancy, but she must be monitored. Women of childbearing age should be advised to avoid pregnancy for 1 month (28 days) following vaccination.

Breastfeeding is NOT a contraindication to the Measles Virus vaccine. Studies have shown that while the rubella component of the MMR vaccine may be secreted in breast milk, the measles virus is not. Even if it were, the virus would be neutralized in the infant's digestive tract. Breastfeeding does not interfere with the infant's immune response to their own vaccinations.

The Measles Virus vaccine is specifically indicated for children starting at 12 months of age. It is NOT approved for infants under 6 months because maternal antibodies remain in the infant's system and neutralize the vaccine virus, preventing the child from developing their own long-term immunity. In children, the vaccine is highly effective and has a well-characterized safety profile.

Most adults born before 1957 are presumed to have natural immunity. However, for older adults who are not immune, the vaccine is safe. The primary concern in the geriatric population is the presence of underlying chronic conditions or medications that might suppress the immune system. Efficacy remains high in healthy older adults.

Patients with renal failure or those on dialysis can safely receive the Measles Virus vaccine, provided they are not otherwise immunocompromised. No dosage adjustments are necessary as the vaccine does not rely on renal excretion.

There are no specific dosing adjustments for hepatic impairment. In patients with stable chronic liver disease (e.g., Hepatitis B or C), the vaccine is recommended. In patients with decompensated cirrhosis, a specialist should evaluate immune function before administration.

> Important: Special populations require individualized medical assessment to ensure that the benefits of protection against measles outweigh the theoretical risks of a live-attenuated vaccine.

The Measles Virus (Live, Attenuated) acts as an immunizing agent. Upon subcutaneous injection, the attenuated virus infects cells and replicates. This process mimics a natural infection but at a significantly reduced level of virulence. The viral antigens are processed and presented to T-cells. This leads to the production of neutralizing IgG antibodies and the creation of memory B and T cells. These memory cells provide rapid and robust protection if the individual is ever exposed to the wild-type measles virus.

• Onset of Action: Antibodies typically become detectable 10 to 14 days after vaccination.
• Duration of Effect: In most individuals, a two-dose series provides lifelong immunity.
• Peak Effect: Maximum antibody titers are usually reached 4 to 6 weeks after the second dose.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous Injection) |

| Protein Binding | N/A |

| Half-life | N/A (Viral clearance depends on immune response) |

| Tmax (Viral Replication) | 7-12 days |

| Metabolism | Intracellular Proteolysis |

| Excretion | Not renally or fecally excreted |

The vaccine consists of the Edmonston-Enders strain of measles virus. It is a negative-sense, single-stranded RNA virus. The virus is grown in chick embryo cell cultures and then lyophilized. The final product contains trace amounts of neomycin, sorbitol, and hydrolyzed gelatin as stabilizers. It is soluble in the provided sterile water diluent, forming a clear to light yellow solution.

Measles Virus is classified as a Vaccine, Live, Attenuated [EPC]. It is often grouped with other live viral vaccines like Mumps, Rubella, Varicella, and Yellow Fever. Within the broader therapeutic area of anti-infectives, it is categorized as a biological agent for active prophylaxis.